Glycated albumin is independently associated with estimated glomerular filtration rate in nondiabetic patients with chronic kidney disease

Clinica Chimica Acta

Volumn 412, Issue 7-8, 2011, Pages 583-586

  Ma, Wen Ya ^a   Wu, Chia Chao ^b   Pei, Dee ^a   Hung, Kuo Chin ^a   Hsia, Te Lin ^a   Su, Ching Chieh ^a   Chu, Yi Min ^a   Lu, Kuo Cheng ^a  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Chronic kidney disease; Glomerular filtration rate; Glycated albumin

Indexed keywords

GLYCOSYLATED ALBUMIN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

FEMALE; GLOMERULAR FILTRATION RATE; GLYCOSYLATION; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; SERUM ALBUMIN;

EID: 79551469460     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.12.013     Document Type: Article

References (31)

1. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003, 108:2154-2169.
2. Shishehbor M.H., Oliveira L.P.J., Lauer M.S., Sprecher D.L., Wolski K., Cho L., et al. Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am. J. Cardiol. 2008, 101:1741-1746.
3. Shinohara K., Shoji T., Emoto M., Tahara H., Koyama H., Ishimura E., et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J. Am. Soc. Nephrol. 2002, 13:1894-1900.
4. Peppa M., Uribarri J., Cai W., Lu M., Vlassara H. Glycoxidation and inflammation in renal failure patients. Am. J. Kidney Dis. 2004, 43:690-695.
5. Stam F., Schalkwijk C.G., van Guldener C., ter Wee P.M., Stehouwer C.D.A. Advanced glycation end-product peptides are associated with impaired renal function, but not with biochemical markers of endothelial dysfunction and inflammation, in non-diabetic individuals. Nephrol. Dial. Transplant. 2006, 21:677-682.
6. Selvaraj N., Bobby Z., Das A.K., Ramesh R., Koner B.C. An evaluation of concentration of oxidative stress and protein glycation in nondiabetic undialyzed chronic renal failure patients. Clin. Chim. Acta 2002, 324:45-50.
7. Winocour P.H., Bhatnagar D., Kalsi P., Hillier V.F., Anderson D.C. A comparison of direct measures of glycaemia and glycated blood proteins in insulin-dependent diabetes mellitus. Clin. Biochem. 1989, 22:457-461.
8. Schleicher E., Mayer R., Wagner E., Gerbitz K. Is serum fructosamine assay specific for determination of glycated serum protein?. Clin. Chem. 1988, 34:320-323.
9. Kouzuma T., Usami T., Yamakoshi M., Takahashi M., Imamura S. An enzymatic method for the measurement of glycated albumin in biological samples. Clin. Chim. Acta 2002, 324:61-71.
10. Inaba M., Okuno S., Kumeda Y., Yamada S., Imanishi Y., Tabata T., et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J. Am. Soc. Nephrol. 2007, 18:896-903.
11. Chujo K., Shima K., Tada H., Oohashi T., Minakuchi J., Kawashima S. Indicators for blood glucose control in diabetics with end-stage chronic renal disease: GHb vs. glycated albumin (GA). J Med Invest 2006, 53:223-228.
12. Yamada S., Inaba M., Shidara K., Okada S., Emoto M., Ishimura E., et al. Association of glycated albumin, but not glycated hemoglobin, with peripheral vascular calcification in hemodialysis patients with type 2 diabetes. Life Sci. 2008, 83:516-519.
13. Pu L.J., Lu L., Shen W.F., Zhang Q., Zhang R.Y., Zhang J.S., et al. Increased serum glycated albumin concentration is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. Circ. J. 2007, 71:1067-1073.
14. Cohen M.P., Ziyadeh F.N., Chen S. Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications. J. Lab. Clin. Med. 2006, 147:211-219.
15. Vijay Viswanathan S.K., Priyanka Tilak, Muthukumaran Parthiban Concentrations of glycated albumin at different stages of diabetic nephropathy in India. Int. J. Diab. Metab. 2009, 17:77-80.
16. Rodiño-Janeiro B.K., González-Peteiro M., Ucieda-Somoza R., González-Juanatey J.R., Álvarez E. Glycated albumin, a precursor of advanced glycation end-products, up-regulates NADPH oxidase and enhances oxidative stress in human endothelial cells: molecular correlate of diabetic vasculopathy. Diab./Metab. Res. Rev. 2010, 26:550-558.
17. Li Y., Wang S. Glycated albumin up-regulates upstream stimulatory factor 2 gene transcription in mesangial cells. Am. J. Physiol. Ren. Physiol. 2010, 299:F121-F127.
18. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann. Intern. Med. 1999, 130:461-470.
19. Levey A.S., Greene T., Kusek J., Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J. Am. Soc. Nephrol. 2000, 11:155A.
20. K/DOQI clinical practice guidelines for chronic kidney disease Evaluation, classification, and stratification. Am. J. Kidney Dis. 2002, 39:S1-S266.
21. Little R.R., Rohlfing C.L., Wiedmeyer H.-M., Myers G.L., Sacks D.B., Goldstein D.E. The national glycohemoglobin standardization program: a five-year progress report. Clin. Chem. 2001, 47:1985-1992.
22. Koga M., Murai J., Saito H., Matsumoto S., Kasayama S. Effects of thyroid hormone on serum glycated albumin concentrations: study on non-diabetic subjects. Diab. Res. Clin. Pract. 2009, 84:163-167.
23. Koga M., Saito H., Mukai M., Otsuki M., Kasayama S. Serum glycated albumin concentrations are influenced by smoking status, independent of plasma glucose concentrations. Acta Diabetol. 2009, 46:141-144.
24. Koga M., Otsuki M., Matsumoto S., Saito H., Mukai M., Kasayama S. Negative association of obesity and its related chronic inflammation with serum glycated albumin but not glycated hemoglobin concentrations. Clin. Chim. Acta 2007, 378:48-52.
25. Freedman B.I., Shihabi Z.K., Andries L., Cardona C.Y., Peacock T.P., Byers J.R., et al. Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease. Am. J. Nephrol. 2010, 31:375-379.
26. Donnelly S.M. Accumulation of glycated albumin in end-stage renal failure: evidence for the principle of "physiological microalbuminuria". Am. J. Kidney Dis. 1996, 28:62-66.
27. Ziyadeh F.N., Han D.C., Cohen J.A., Guo J., Cohen M.P. Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor-[bgr] system. Kidney Int. 1998, 53:631-638.
28. Chen S., Cohen M.P., Ziyadeh F.N. Amadori-glycated albumin in diabetic nephropathy: pathophysiologic connections. Kidney Int. Suppl. 2000, 77:S40-S44.
29. Ghiggeri G.M., Candiano G., Delfino G., Bianchini F., Queirolo C. Glycosyl albumin and diabetic microalbuminuria: demonstration of an altered renal handling. Kidney Int. 1984, 25:565-570.
30. Margo P.C., Elizabeth S., Sheldon C., Clyde W.S. Glycated albumin increases oxidative stress, activates NF-κB and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-κ1 production in macrophage RAW cells. J. Lab. Clin. Med. 2003, 141:242-249.
31. Schleicher E., Olgemoller B., Wiedenmann E., Gerbitz K. Specific glycation of albumin depends on its half-life. Clin. Chem. 1993, 39:625-628.